Shillong Herald

Cardiac Amyloidosis Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest Drug Approvals, Emerging Drugs| Pfizer, BSIM Therapeutics, Neurimmune AG, Intellia, Alexion, Ionis

 Breaking News
  • No posts were found

Cardiac Amyloidosis Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest Drug Approvals, Emerging Drugs| Pfizer, BSIM Therapeutics, Neurimmune AG, Intellia, Alexion, Ionis

May 24
17:36 2023
Cardiac Amyloidosis Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest Drug Approvals, Emerging Drugs| Pfizer, BSIM Therapeutics, Neurimmune AG, Intellia, Alexion, Ionis
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cardiac Amyloidosis pipeline constitutes 20+ key companies continuously working towards developing 20+ Cardiac Amyloidosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Cardiac Amyloidosis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cardiac Amyloidosis Market.

 

The Cardiac Amyloidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Cardiac Amyloidosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Cardiac Amyloidosis treatment therapies with a considerable amount of success over the years. 
  • Cardiac Amyloidosis companies working in the treatment market are BSIM Therapeutics, Neurimmune AG, Intellia Therapeutics, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, and others, are developing therapies for the Cardiac Amyloidosis treatment 
  • Emerging Cardiac Amyloidosis therapies such as – BSIM-3A05D, NI006, NTLA-2001, ALXN 2060, Eplontersen, Tafamidis, and others are expected to have a significant impact on the Cardiac Amyloidosis market in the coming years.   
  • In January 2022, In order to create NI006, an experimental human monoclonal antibody that focuses on misfolded transthyretin, Neurimmune AG stated that it had entered into an exclusive global partnership and licence agreement with Alexion, AstraZeneca’s Rare Disease group
  • On January 24, 2022, Ionis Pharmaceuticals, Inc. declared today that eplontersen, an experimental antisense medication for the treatment of persons with transthyretin-mediated amyloidosis, had been given orphan drug status by the U.S. Food and medication Administration (FDA)
  • In December 2021, With regard to eplontersen, formerly known as IONIS-TTR-LRX, AstraZeneca and Ionis Pharmaceuticals, Inc. (Ionis) have entered into a new global development and commercialization agreement
  • In March 2020, To assess the effectiveness and safety of ION-682884 in patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), Ionis Pharmaceuticals started a Phase III global, doubleblind, randomised, placebo-controlled research

 

Cardiac Amyloidosis Overview

In the heart disorder known as cardiac amyloidosis, misshaped proteins accumulate in and around various heart organs. The heart works harder to pump blood when these proteins accumulate because it finds it difficult to do so. The increased effort eventually causes the heart to weaken and suffer damage, failing.

 

Get a Free Sample PDF Report to know more about Cardiac Amyloidosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/cardiac-amyloidosis-pipeline-insight

 

Emerging Cardiac Amyloidosis Drugs Under Different Phases of Clinical Development Include:

  • BSIM-3A05D: BSIM Therapeutics
  • NI006: Neurimmune AG
  • Acoramidis: Eidos Therapeutics
  • NTLA-2001: Intellia Therapeutics
  • ALXN 2060: Alexion Pharmaceuticals
  • Eplontersen: Ionis Pharmaceuticals

 

Route of Administration

Cardiac Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Cardiac Amyloidosis Pipeline Therapeutics Assessment

  • Cardiac Amyloidosis Assessment by Product Type
  • Cardiac Amyloidosis By Stage and Product Type
  • Cardiac Amyloidosis Assessment by Route of Administration
  • Cardiac Amyloidosis By Stage and Route of Administration
  • Cardiac Amyloidosis Assessment by Molecule Type
  • Cardiac Amyloidosis by Stage and Molecule Type

 

DelveInsight’s Cardiac Amyloidosis Report covers around 20+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Cardiac Amyloidosis product details are provided in the report. Download the Cardiac Amyloidosis pipeline report to learn more about the emerging Cardiac Amyloidosis therapies

 

Cardiac Amyloidosis Pipeline Analysis:

The Cardiac Amyloidosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cardiac Amyloidosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cardiac Amyloidosis Treatment.
  • Cardiac Amyloidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cardiac Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cardiac Amyloidosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Cardiac Amyloidosis drugs and therapies

 

Cardiac Amyloidosis Pipeline Market Drivers

  • Improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Cardiac Amyloidosis Market.

 

Cardiac Amyloidosis Pipeline Market Barriers

  • However, high cost of treatment, lack of awareness regarding the cardiac amyloidosis in developing countries and other factors are creating obstacles in the Cardiac Amyloidosis Market growth.

 

Scope of Cardiac Amyloidosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Cardiac Amyloidosis Companies: BSIM Therapeutics, Neurimmune AG, Intellia Therapeutics, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, and others
  • Key Cardiac Amyloidosis Therapies: BSIM-3A05D, NI006, NTLA-2001, ALXN 2060, Eplontersen, Tafamidis, and others
  • Cardiac Amyloidosis Therapeutic Assessment: Cardiac Amyloidosis current marketed and Cardiac Amyloidosis emerging therapies
  • Cardiac Amyloidosis Market Dynamics: Cardiac Amyloidosis market drivers and Cardiac Amyloidosis market barriers 

 

Request for Sample PDF Report for Cardiac Amyloidosis Pipeline Assessment and clinical trials

 

Table of Contents

1

Cardiac Amyloidosis Report Introduction

2

Cardiac Amyloidosis Executive Summary

3

Cardiac Amyloidosis Overview

4

Cardiac Amyloidosis- Analytical Perspective In-depth Commercial Assessment

5

Cardiac Amyloidosis Pipeline Therapeutics

6

Cardiac Amyloidosis Late Stage Products (Phase II/III)

7

Cardiac Amyloidosis Mid Stage Products (Phase II)

8

Cardiac Amyloidosis Early Stage Products (Phase I)

9

Cardiac Amyloidosis Preclinical Stage Products

10

Cardiac Amyloidosis Therapeutics Assessment

11

Cardiac Amyloidosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Cardiac Amyloidosis Key Companies

14

Cardiac Amyloidosis Key Products

15

Cardiac Amyloidosis Unmet Needs

16 

Cardiac Amyloidosis Market Drivers and Barriers

17

Cardiac Amyloidosis Future Perspectives and Conclusion

18

Cardiac Amyloidosis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles